Stock RGBP REGEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 07:40:55 17/05/2024 pm IST 		5-day change 1st Jan Change
0.7 USD +0.72% Intraday chart for Regen BioPharma, Inc. +3.70% -26.32%
24/04 Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
09/02 Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 2.068 0.66 0.2195 130.2 32.71 6.329
Enterprise Value (EV) 1 3.492 2.799 2.824 133.1 33.93 6.964
P/E ratio -0.38 x -0.87 x 0.12 x -13.5 x 13.7 x 6.24 x
Yield - - - - - -
Capitalization / Revenue 20.7 x 6 x 2 x 761 x 139 x 26.8 x
EV / Revenue 34.9 x 25.4 x 25.7 x 777 x 144 x 29.4 x
EV / EBITDA - - - - - -
EV / FCF 1.62 x 3.6 x -0.68 x 23 x -8.4 x -3.15 x
FCF Yield 61.7% 27.8% -147% 4.35% -11.9% -31.8%
Price to Book -0.23 x -0.06 x -0.07 x -9.78 x -4.05 x -1.24 x
Nbr of stocks (in thousands) 117 400 488 2,852 3,354 3,506
Reference price 2 17.70 1.650 0.4500 45.65 9.750 1.805
Announcement Date 27/12/18 21/06/21 04/08/21 22/12/21 15/11/22 20/11/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales 1 0.1 0.11 0.11 0.1712 0.2355 0.2366
EBITDA - - - - - -
EBIT 1 -1.426 -0.8749 -0.2093 -0.2008 -0.3396 -0.6869
Operating Margin -1,425.78% -795.37% -190.29% -117.28% -144.2% -290.39%
Earnings before Tax (EBT) 1 -4.715 -2.623 3.414 -6.765 2.444 1.157
Net income 1 -4.715 -2.623 3.414 -6.765 2.444 1.157
Net margin -4,715.2% -2,384.71% 3,104.02% -3,951.79% 1,037.52% 488.89%
EPS 2 -46.50 -1.900 3.633 -3.370 0.7102 0.2894
Free Cash Flow 1 2.156 0.777 -4.146 5.794 -4.039 -2.212
FCF margin 2,156.34% 706.33% -3,769.44% 3,384.61% -1,714.96% -934.92%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 27/12/18 21/06/21 04/08/21 22/12/21 15/11/22 20/11/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 1.42 2.14 2.6 2.86 1.22 0.64
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 2.16 0.78 -4.15 5.79 -4.04 -2.21
ROE (net income / shareholders' equity) 65.6% 26.2% -37.4% 65% -22.7% -17.6%
ROA (Net income/ Total Assets) -155% -355% -118% -18.8% -24% -94.1%
Assets 1 3.051 0.739 -2.901 36 -10.19 -1.229
Book Value Per Share 2 -76.00 -27.40 -6.890 -4.670 -2.410 -1.460
Cash Flow per Share 2 0.0700 0.0200 - 0.2500 0.0200 0.0300
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 27/12/18 21/06/21 04/08/21 22/12/21 15/11/22 20/11/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGEN BIOPHARMA, INC. Stock Regen BioPharma, Inc.
-26.32% 2.9M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.73% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.88% 104B
BIONTECH SE Stock BioNTech SE
-12.79% 22.41B
ARGENX SE Stock argenx SE
-1.11% 22.28B
GENMAB A/S Stock Genmab A/S
-5.29% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.97% 17.89B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.88% 14.28B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.43% 12.55B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RGBP Stock
  4. Financials Regen BioPharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW